Motivated by these findings, we evaluated the apoptotic induction efficiency of BCS3 through the direct inhibition of IAPs and the modulation of MDM2-p53-caspases and p53-p21-CDK1/cyclin B1 axes both in vitro and in vivo to enhance tumor sensitization. This evidence concerns the gene TP53 and neoplasm.